| Literature DB >> 20875282 |
Jay K Varma1, Kimberly D McCarthy, Theerawit Tasaneeyapan, Patama Monkongdee, Michael E Kimerling, Eng Buntheoun, Delphine Sculier, Chantary Keo, Praphan Phanuphak, Nipat Teeratakulpisarn, Nibondh Udomsantisuk, Nguyen H Dung, Nguyen T N Lan, Nguyen T B Yen, Kevin P Cain.
Abstract
Bloodstream infections (BSIs) are a major cause of illness in HIV-infected persons. To evaluate prevalence of and risk factors for BSIs in 2,009 HIV-infected outpatients in Cambodia, Thailand, and Vietnam, we performed a single Myco/F Lytic blood culture. Fifty-eight (2.9%) had a clinically significant BSI (i.e., a blood culture positive for an organism known to be a pathogen). Mycobacterium tuberculosis accounted for 31 (54%) of all BSIs, followed by fungi (13 [22%]) and bacteria (9 [16%]). Of patients for whom data were recorded about antiretroviral therapy, 0 of 119 who had received antiretroviral therapy for ≥14 days had a BSI, compared with 3% of 1,801 patients who had not. In multivariate analysis, factors consistently associated with BSI were fever, low CD4+ T-lymphocyte count, abnormalities on chest radiograph, and signs or symptoms of abdominal illness. For HIV-infected outpatients with these risk factors, clinicians should place their highest priority on diagnosing tuberculosis.Entities:
Mesh:
Year: 2010 PMID: 20875282 PMCID: PMC3294385 DOI: 10.3201/eid1610.091686
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Clinically significant organisms isolated from cultures of blood samples from 2,009 HIV-infected outpatients from Thailand, Cambodia, and Vietnam, September 2006–July 2008
| Organism | No. (%), n = 58 |
|---|---|
| Mycobacteria | 36 (62) |
|
| 31 (86) |
|
| 3 (8) |
|
| 1 (3) |
| Non-tuberculous mycobacteria not identified | 1 (3) |
| Other bacteria | 9 (16) |
| Non-Typhi | 2 (22) |
|
| 3 (33) |
|
| 1 (11) |
|
| 2 (22) |
|
| 1 (11) |
| Fungi | 13 (22) |
|
| 6 (46) |
|
| 5 (38) |
|
| 1 (8) |
| Non-albicans | 1 (8) |
Characteristics of 2,009 HIV-infected outpatients and associated BSI, Thailand, Cambodia, and Vietnam, September 2006–July 2008*
| Characteristic | All, no. (%), N = 2,009 | Have BSI†, no./total (%), n = 58 | Do not have BSI, no./total (%), n = 1,951 | OR (95% CI) |
|---|---|---|---|---|
| Demographics | ||||
| Country of origin | ||||
| Thailand | 630 (31) | 5/58 (9) | 625/1,951 (32) | Referent |
| Cambodia | 945 (47) | 31/58 (53) | 914/1,951 (47) | 4.2 (1.6–11.0) |
| Vietnam | 434 (22) | 22/58 (38) | 412/1,951 (21) | 6.7 (2.5–17.8) |
| Median age, y (IQR)‡ | 31 (27–38) | 32 (27–36) | 31 (27–38) | NS |
| Male sex | 1,019 (51) | 40/58 (69) | 979/1,951 (50) | 2.21 (1.26–3.88) |
| Medical history | ||||
| History of injection drug use | 255 (13) | 15/58 (26) | 240/1,950 (12) | 2.49 (1.36–4.54) |
| HIV diagnosed in past 14 d§ | 853 (43) | 33/58 (57) | 820/1,951 (42) | 1.80 (1.06–3.05) |
| Received ART for | 119 (6) | 0/58 (0) | 119/1,862 (6) | 0 |
| Took co-trimoxazole | 232 (12) | 12/58 (21) | 220/1,950 (11) | 2.05 (1.07–3.93) |
| Took other antimicrobial drug | 194 (10) | 12/58 (21) | 182/1,951 (9) | 2.54 (1.32–4.87) |
| Constitutional symptoms¶ | ||||
| Fever | 398 (20) | 36/58 (62) | 362/1,950 (19) | 10.54 (4.51–24.65) |
| Fever lasting | 313 (16) | 32/58 (55) | 281/1,948 (14) | 7.30 (4.29–12.44) |
| Shaking chills | 204 (10) | 19/58 (33) | 185/1,946 (10) | 4.64 (2.63–8.19) |
| Night sweats | 309 (15) | 25/58 (43) | 284/1,949 (15) | 4.44 (2.60–7.58) |
| Night sweats lasting | 199 (10) | 16/57 (28) | 183/1,943 (9) | 3.75 (2.07–6.82) |
| Respiratory symptoms | ||||
| Cough | 688 (34) | 39/58 (67) | 649/1,949 (33) | 4.11 (2.36–7.17) |
| Every day | 811 (40) | 40/58 (69) | 771/1,949 (40) | 3.40 (1.93–5.97) |
| Recently worsened | 72 (4) | 7/58 (12) | 65/1947 (3) | 3.97 (1.74–9.09) |
| Lasting | 380 (19) | 22/58 (38) | 358/1,946 (18) | 2.71 (1.58–4.66) |
| Difficulty breathing | 428 (21) | 32/58 (55) | 396/1,951 (20) | 4.83 (2.85–8.2) |
| Chest pain | 419 (21) | 30/58 (52) | 389/1,951 (20) | 4.30 (2.54–7.29) |
| Gastrointestinal symptoms | ||||
| Mouth or throat pain | 403 (20) | 27/58 (47) | 376/1,951 (19) | 3.65 (2.15–6.19) |
| Pain with swallowing | 282 (14) | 21/58 (36) | 261/1,949 (13) | 3.67 (2.12–6.37) |
| Abdominal pain | 321 (16) | 20/58 (35) | 301/1,951 (15) | 2.89 (1.66–5.03) |
| Loss of appetite | 471 (23) | 38/57 (67) | 433/1,951 (22) | 7.01 (4.00–12.29) |
| Nausea or vomiting | 250 (12) | 22/58 (38) | 228/1,950 (12) | 4.62 (2.67–7.98) |
| Diarrhea | 185 (9) | 19/58 (33) | 166/1,949 (9) | 5.23 (2.96–9.26) |
| Diarrhea lasting | 94 (5) | 7/58 (12) | 87/1,948 (5) | 2.94 (1.29–6.66) |
| Neurologic-muscular symptoms | ||||
| Lightheadedness | 507 (25) | 28/58 (48) | 479/1,947 (25) | 2.86 (1.69–4.84) |
| Fatigue | 875 (44) | 48/58 (83) | 827/1,949 (42) | 6.51 (3.28–12.95) |
| Muscle weakness | 523 (26) | 33/58 (57) | 490/1,950 (25) | 3.93 (2.32–6.68) |
| Difficulty sleeping | 630 (31) | 36/58 (62) | 594/1,948 (31) | 3.73 (2.18–6.39) |
| Numbness in feet | 420 (21) | 25/58 (43) | 395/1,949 (20) | 2.98 (1.75–5.07) |
| Signs | ||||
| Temperature >38◦C | 128 (6) | 25/58 (43) | 103/1,949 (5) | 13.58 (7.78–23.68) |
| Heart rate | 231 (11) | 22/58 (38) | 209/19,48 (11) | 5.08 (2.94–8.81) |
| Body mass index <18.5 | 546 (27) | 34/58 (59) | 512/1,950 (26) | 3.98 (2.34–6.77) |
| Thrush | 249 (12) | 25/58 (43) | 224/1,949 (12) | 5.83 (3.41–9.99) |
| Oral hairy leukoplakia | 166 (8) | 19/58 (33) | 147/1,949 (8) | 5.97 (3.37–10.6) |
| Oral ulcerations | 128 (6) | 12/58 (21) | 116/1,948 (6) | 4.12 (2.12–7.99) |
| Jaundice | 15 (1) | 3/58 (5) | 12/1,949 (1) | 8.80 (2.42–32.09) |
| Any lymphadenopathy# | 238 (12) | 18/58 (31) | 220/1,945 (11) | 3.53 (1.99–6.26) |
| Head and neck lymphadenopathy | 181 (9) | 18/58 (31) | 163/1,945 (8) | 4.92 (2.76–8.78) |
| Papular rash | 402 (20) | 18/58 (31) | 384/1,949 (20) | 1.83 (1.04–3.23) |
| Needle tracks on arms | 42 (2) | 5/58 (9) | 37/1,949 (2) | 4.88 (1.84–12.9) |
| CD4+ T-lymphocyte count | ||||
| CD4 count, median (IQR) | 252 (92–401) | 15 (8–50) | 261 (102–405) | p < 0.01 |
| <50 cells/mm3 | 350 (17) | 44/58 (76) | 306/1,934 (16) | 16.72 (9.05–30.89) |
| <100 cells/mm3 | 529 (26) | 50/58 (86) | 479/1,934 (25) | 18.98 (8.94–40.33) |
| <200 cells/mm3 | 810 (40) | 53/58 (91) | 757/1,934 (39) | 16.48 (6.56–41.42) |
| <250 cells/mm3 | 988 (49) | 53/58 (91) | 935/1,934 (48) | 11.33 (4.51–28.46) |
| Karnofsky score <70 | 85 (4) | 7/58 (12) | 78/1,945 (4) | 3.29 (1.44–7.47) |
| Hematologic tests | ||||
| Hemoglobin level <12 g/dL | 777 (39) | 46/53 (87) | 731/1,913 (38) | 10.63 (4.77–23.66) |
| Leukocyte count >12 × 103 cells/µL | 1,189 (59) | 12/53 (23) | 50/1,893 (3) | 10.79 (5.35–21.77) |
| Thrombocyte count <100 × 103cells/µL | 145 (7) | 11/58 (19) | 134/1,951 (7) | 3.17 (1.61–6.26) |
| Chest radiograph | ||||
| Abnormal chest radiograph | 457 (23) | 36/58 (62) | 421/1,925 (22) | 5.85 (3.4–10.04) |
| Interstitial pattern | 82 (4) | 10/58 (17) | 72/1,951 (4) | 5.44 (2.64–11.18) |
| Any infiltrate | 266 (13) | 19/58 (33) | 247/1,951 (13) | 3.36 (1.91–5.91) |
| Miliary pattern | 25 (1) | 7/58 (12) | 18/1,951 (1) | 14.74 (5.90–36.85) |
| Pleural effusion | 39 (2) | 4/58 (7) | 35/1,951 (2) | 4.06 (1.39–11.81) |
| Mass or nodule | 57 (3) | 8/58 (14) | 49/1,951 (3) | 6.21 (2.80–13.8) |
| Paratracheal adenopathy | 70 (3) | 14/58 (24) | 56/1,951 (3) | 10.77 (5.58–20.78) |
| >1/3 of either lung abnormal | 108 (5) | 14/58 (24) | 94/1,951 (5) | 6.29 (3.33–11.87) |
| Any lower lung field abnormality | 194 (10) | 22/58 (38) | 172/1,951 (9) | 6.32 (3.64–10.99) |
| Any upper lung field abnormality | 258 (13) | 20/58 (35) | 238/1,951 (12) | 3.79 (2.17–6.62) |
*Characteristics displayed include those postulated to be associated with BSI that were statistically significant in bivariate analysis. BSI, bloodstream infection; OR, odds ratio; CI, confidence interval; IQR, interquartile range; NS, not significant; ART, antiretroviral therapy. †Patients whose blood culture grew a contaminant or had no growth were classified as having no BSI. ‡Age was analyzed as a continuous variable with an OR calculated by using logistic regression; p = 0.46. §The exact date of HIV diagnosis was missing for 12 patients. ¶Unless specified, patients were asked about any occurrence of this symptom in the past 24 h. #Defined as having a peripheral, noninguinal lymph node >1 cm in diameter or a peripheral, inguinal lymph node >2 cm in diameter.
Multivariate analysis of risk factors for clinically significant BSI caused by mycobacterial or other bacterial infection in HIV-infected outpatients, Thailand, Cambodia, and Vietnam, September 2006–July 2008*
| Characteristic | Adjusted odds ratio (95% CI) for BSI | ||
|---|---|---|---|
| Any pathogen† | Mycobacteria‡ | Bacteria§ | |
| CD4 cell count <100/mm3 | 5.8 (2.5–13.7) | 11.2 (3.0–41.3) | – |
| Female sex | 0.4 (0.2–0.9) | – | – |
| Fever in past 24 h | – | – | 4.7 (1.2–17.6) |
| Loss of appetite in past 24 h | 2.0 (1.0–3.9) | – | – |
| Nausea or vomiting in past 24 h | 2.5 (1.2–5.0) | – | – |
| Shaking chills in past 24 h | – | 3.1 (1.1–9.1) | – |
| Difficulty breathing | – | 4.1 (1.5–11.1) | – |
| Diarrhea in past 24 h | – | 4.2 (1.6–11.3) | – |
| Jaundice | – | – | 12.5 (1.4–112.3) |
| Ever injected drug | – | – | – |
| Temperature >38°C | 3.2 (1.6–6.3) | 5.7 (2.1–15.4) | – |
| Heart rate >100 bpm | – | – | – |
| Oral hairy leukoplakia | 2.8 (1.4–5.7) | – | – |
| Hemoglobin level <12 g/dL | 4.8 (2.0–11.7) | – | – |
| Leukocyte count >12 × 103/µL | 3.7 (1.4–9.3) | 15.3 (4.9–48.2) | – |
| Thrombocyte count <100,000 cells/µL | – | 7.0 (1.8–27.6) | – |
| Paratracheal adenopathy on chest radiograph | 5.0 (2.1–11.6) | 11.3 (3.7–34.3) | – |
| Miliary pattern on chest radiograph | 6.0 (1.8–19.5) | 14.2 (3.4–58.6) | – |
| Took antimicrobial medication other than cotrimoxazole | – | 5.1 (1.6–16.8) | – |
*BSI, bloodstream infection; CI, confidence interval; bpm, beats per minute; –, variable was not included in the model. †1,961 patients in final model. ‡1,944 patients in final model. §1,961 patients in final model.
| 1. The activity supported the learning objectives. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 2. The material was organized clearly for learning to occur. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 3. The content learned from this activity will impact my practice. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |
| 4. The activity was presented objectively and free of commercial bias. | ||||
| Strongly Disagree | Strongly Agree | |||
| 1 | 2 | 3 | 4 | 5 |